CAMPBELL, CA–(Marketwired – Apr 14, 2016) – Friendable, Inc. (OTC PINK: FDBL), a mobile application developer, is pleased to announce that its submission of a major app update for Friendable iOS/iPhone users has been approved and is now available in the Apple iTunes App Store. These major app updates completed in the iOS version of the Friendable app were designed to spur new user downloads and registrations.
Among the upgrades included are the following features:
Users can now sign in and connect using Facebook, the world’s largest social network.
A new proprietary location database connected to Google Places.
An all-new registration and onboarding process, making the signup process faster and simpler.
Event selectors are now icon based, adding ease and charm to each action.
Updated User Interface (UI) to the all-important member profile screens.
“Our entire team is in agreement, these updates significantly improve the user experience for iOS users making the Friendable app even friendlier,” said Robert Rositano, Jr., CEO, Friendable, Inc. “The updated integration with Facebook is a big deal for us, among various other advancements and by using a trusted verification platform like Facebook to incent users to login using this method, is just one more feature that will improve the user experience. We expect these changes to significantly increase new user signups and provide the foundation to boost revenue opportunities as we continue our focus on overall user population and growth.”
About Friendable: Friendable Inc. is a mobile application developer whose Friendable app makes it simple and easy for users to make connections and meet new friends using shared interests and location. These interactions allow Friendable to generate ad revenue by providing advertisers such as restaurants, bars and events with the opportunity to reach potential customers when it matters most: which is when Friendable users are nearby and searching for something to do.
Cautionary Language Concerning Forward-Looking Statements This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected by Friendable, Inc. The iTunes rankings should not be construed as an indication in any way whatsoever of the future value of the Friendable’s common stock or its present or future financial condition. The public filings of Friendable, Inc. made with the Securities and Exchange Commission may be accessed at the SEC’s Edgar system atwww.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Friendable, Inc. cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, Friendable, Inc. does not undertake, and Friendable, Inc. specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.
In 2016, Moderna received $8 million with the potential for up to $125 million from the Biomedical Advanced Research and Development Authority, a component of the U.S. Department of Health and Human Services, to accelerate development of an mRNA vaccine for Zika. (The company is still working on that project.)What makes the bankrolling of Moderna’s Covid-19 vaccine so extraordinary, Foroohar said, was the scale, which “reflects how unusual the pandemic is and the fact that this is very literally a once-in-a-lifetime event.”
The following year, it was bought by Gilead NASDAQ: GILD and its immunotherapy subsidiary, Kite, for $567 million. Since then, Kite has begun recruiting for a clinical trial of its solid tumor CAR-T candidate, but it has not yet moved past Phase 1.
The three-year collaboration, announced Wednesday, has initial funding of $7.28 million.Current gene therapy approaches being developed for sickle cell disease are complex, enormously expensive, and bespoke, crafting treatments for individual patients one at a time. The collaboration aims to instead create an off-the-shelf treatment that bypasses many of the steps of current approaches, in which cells are removed and processed outside the body before being returned to patients.
Efficacy rates for China’s Covid vaccines have been found to be lower than those developed by Pfizer-BioNTech (NYSE PFE) (NASDAQ:BNTX) and Moderna. (NASDAQ MRNA) Earlier this month, the director of the Chinese Center for Disease Control publicly acknowledged that Chinese vaccines “don’t have very high protection rates” and that they were considering giving people different Covid shots to boost vaccine efficacy.
From January 2020 through January of this year, Moderna stock has dropped significantly three times. And each time, it recovered and climbed above its previous record high. It looks like that now may be happening for the fourth time. This may be a pattern of investors locking in profits, then repurchasing shares at a lower price -- and newcomers jumping aboard too.